Xtant Medical Holdings Inc (XTNT)
XASE:XTNT
Want to see XTNT full AI Analyst Report?
Earnings Data
Report Date
Jul 30, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.02Last Year’s EPS
-0.09Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call mixed material strategic and balance-sheet positives with near-term operational and revenue challenges. Key strategic wins (HEMOBLAST distribution, Trivium Shaped launch, Companion Spine proceeds) and reduced indebtedness position the company for growth and improved liquidity, and management raised FY2026 revenue guidance. However, Q1 operating metrics were weak: revenue fell ~36.5% year-over-year, gross margin contracted ~4.2 percentage points, the company reported a $3.1M net loss and negative adjusted EBITDA, and cash declined ~29.5% (though revolver availability improved). Management expects margin recovery later in the year and anticipates incremental sales investments to drive adoption, but near-term expense pressure and amnio/OEM headwinds temper the outlook.Company Guidance
Raised Full-Year 2026 Revenue Guidance
Company raised FY2026 revenue guidance to $101.0M–$105.0M, citing the addition of HEMOBLAST Bellows, recent product launches (including Trivium Shaped) and measured investments in the commercial organization as drivers of expected top-line growth.
Exclusive U.S. Distribution Agreement for HEMOBLAST Bellows
Announced exclusive U.S. distribution agreement with Dilon Technologies for HEMOBLAST Bellows, providing entry into an estimated $2.0B global hemostatic market. Deal adds a differentiated hemostat (collagen + human thrombin + bovine chondroitin sulfate), immediate cross-sell potential across biologics portfolio, and included hiring Dilon's team of 21 sales professionals to expand commercial reach.
Companion Spine Transaction Strengthened Balance Sheet
Received final $10.7M from Companion Spine; total purchase price for the divestitures was $21.4M. Proceeds used to reduce borrowings and strengthen liquidity, resulting in a total indebtedness reduction of $13.3M in Q1 2026 (including $10.4M revolver paydown and $2.8M term loan payment).
Product Innovation — Commercial Launch of Trivium Shaped
Commercial launch of Trivium Shaped (pre-shaped Trivium allograft forms such as boats and strips) expands the Trivium platform and targets improved operating-room handling and consistency; management reported positive surgeon feedback and views this as a meaningful commercial and clinical advancement.
Reduced Operating Expenses and Improved Expense Profile
Operating expenses declined to $14.9M in Q1 2026 from $19.2M in Q1 2025 (driven largely by the Companion Spine divestitures). G&A decreased to $6.3M (from $7.5M) and sales & marketing to $8.2M (from $11.2M); R&D remained essentially flat at $0.435M.
Improved Liquidity Availability
Availability under revolving credit facility increased to $11.8M as of March 31, 2026 from $3.8M as of December 31, 2025 (an increase of ~$8.0M, ~210% increase), reflecting lower outstanding revolver balances and reduced interest expense strategy.
XTNT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
XTNT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 13, 2026 | $0.50 | $0.48 | -4.76% |
Mar 31, 2026 | $0.54 | $0.56 | +2.76% |
Nov 10, 2025 | $0.76 | $0.76 | -0.66% |
Aug 12, 2025 | $0.59 | $0.67 | +14.14% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Xtant Medical Holdings Inc (XTNT) report earnings?
Xtant Medical Holdings Inc (XTNT) is schdueled to report earning on Jul 30, 2026, After Close (Confirmed).
What is Xtant Medical Holdings Inc (XTNT) earnings time?
Xtant Medical Holdings Inc (XTNT) earnings time is at Jul 30, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is XTNT EPS forecast?
XTNT EPS forecast for the fiscal quarter 2026 (Q2) is -0.02.